You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
03. Endometrial cancer
#831 Minimally invasive surgery in recurrent endometrial cancer a multicenter study
Free
  1. Virginia Vargiu1,
  2. Andrea Rosati1,
  3. Valerio Gallotta1,
  4. Lucia Tortorella1,
  5. Vito Andrea Capozzi2,
  6. Luca Palmieri3,
  7. Francesco Cosentino4,
  8. Giovanni Scambia3 and
  9. Francesco Fanfani3
  1. 1Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  2. 2Department of Medicine and Surgery, University of Parma, Parma, Italy
  3. 3Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
  4. 4Department of Oncology, Gemelli Molise, Università degli studi del Molise, Campobasso, Italy

Abstract

Introduction/Background Secondary cytoreductive surgery (SCS) is gaining increasing interest in the treatment of endometrial cancer (EC) recurrence. Although the role of minimally invasive surgery (MIS) is well recognized in the initial treatment of EC, there is no data about its safety, in terms of oncological outcomes, in relapsed disease.

Methodology Multicenter retrospective study including patients with first EC relapse subjected to SCS between January2010 and May2022. Primary outcome was to compare oncological outcomes of patients subjected to MIS or open SCS. Secondary outcome was to assess factors that could be favorably associated with MIS. Survival was determined from date of first recurrence to last follow-up or cancer-related death and estimated using Kaplan-Meier method. Differences in survival were analyzed using Log-rank test. Binomial logistic regression was performed to evaluate factors that could predict MIS.

Results Data from 210 patients were retrieved. No differences in terms of post relapse and post relapse free survival were highlighted (log-rank test p=0.235 and p=0.628 respectively). Body mass index (BMI)≥30, early FIGO stage at diagnosis, single site relapse and the hematogenous pattern of relapse (parenchymal relapse) were positively associated with MIS (respectively BMI≥30 OR 2.216, 95% CI: 1.109–4.430, p=0.024; early FIGO stage: OR: 4.294, 95% CI: 1.571–11.737, p=0.005; single site relapse OR: 2.757, 95% CI: 1.059–7.178, p=0.038; hematogenous pattern of relapse OR: 4.322, 95% CI: 1.711–10.918, p=0.002). In contrast, patients who received adjuvant radiotherapy at first diagnosis were less probably operated through MIS (OR 0.444, 95% CI 0.213–0.925, p=0.030) (figure 1).

Conclusion MIS for recurrent EC did not affect surgical outcomes. The early-stage disease at diagnosis, the single site relapse, the evidence of a single parenchymal metastasis (hematogenous pattern) and a BMI over 30 were positively associated with the minimally invasive approach. In contrast, previous radiotherapy was identified as negative predictor.

Abstract #831 Figure 1
Abstract #831 Figure 1

Disclosures None

https://doi.org/10.1136/ijgc-2023-ESGO.378

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.